Navigation Links
New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
Date:10/15/2007

acute,

mild-to-moderate ulcerative colitis

Poster Presentation: Tuesday, October 16, 2007, Exhibit Hall B, #953

-- Long-term remission rates in patients with mild-to-moderate ulcerative

colitis who require a LIALDA dose increase to induce initial remission

Poster Presentation: Monday, October 15, 2007, Exhibit Hall B, #614

About LIALDA

LIALDA is part of a drug class called aminosalicylates, which contain 5-aminosalicyclic acid (5-ASA). 5-ASA is a well-established drug of choice and often a first-line treatment for UC. LIALDA is indicated for the induction of remission in patients with active, mild to moderate UC. The safety and efficacy of LIALDA have been established for up to eight weeks. LIALDA is the first new formulation in this class to be approved since 2000. LIALDA is the only ulcerative colitis treatment that utilizes MMX(R) Technology. LIALDA with MMX Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic excipients.

Shire has licensed from Giuliani SpA the exclusive rights to develop and commercialize LIALDA in the U.S., Canada, Europe -- known as MEZAVANT(TM) -- (excluding Italy) and the Pacific Rim. Giuliani SpA retains the development and commercialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the MMX Technology.

For more information about LIALDA and for Full Prescribing Information, please visit http://www.LIALDA.com.

Important Safety Information

LIALDA tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of LIALDA beyond eight weeks have not been established.

LIALDA is contraindicated in patients with hypersensitivity to sali
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
10. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
11. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... NEW YORK , Sept. 16, 2014 EHE ... exams with a nationwide physician network, today announced that ... has been named an EHE-certified preventive care center. Through ... Tarzana region now have greater access to ... "EHE is proud to add Dr. Abrams ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)...  Decision Resources Group finds that the rheumatoid arthritis (RA) disease-modifying ... over $18.2 billion in 2023 in the United States ... , Italy , Spain , ... . TNF-alpha inhibitors will remain the leading drug class in ... will be constrained and patient shares will decline due to the ...
Breaking Medicine Technology:EHE International Certifies David Abrams M.D. as Its Newest Partner 2QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3
... Newport Corporation (Nasdaq: NEWP ) today announced that it has ... to Dynasil Corporation (OTC Bulletin Board: DYSL), a provider of technology, ... markets. , , ... Hilger, based in Margate, UK, manufactures and sells a variety of ...
... N.Y. , July 20 As of ... standards applicable to devices that measure A1C (or glycated ... (NGSP) changed to +/-0.75% A1C, 95% CI, 4-10.0% A1C ... SELFCHECK devices, submits for annual NGSP certification each June ...
Cached Medicine Technology:Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 2Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 3New Standard of National Glycohemoglobin Standardization Program 2New Standard of National Glycohemoglobin Standardization Program 3
(Date:9/16/2014)... electronic activity monitors hold great promise in helping ... These increasingly sophisticated devices help the wearers improve ... bodily responses. This information is organized into companion ... the large and quickly growing market for these ... Branch at Galveston analyzed 13 of these activity ...
(Date:9/16/2014)... DC September 14, 2014 A ... everolimus-eluting stents (EES) and drug-eluting balloons (DEB) ... stents found that EES provided superior late ... , Findings were reported today at ... scientific symposium. Sponsored by the Cardiovascular Research ...
(Date:9/16/2014)... Seven heroes who have dramatically improved ... honored in New York City on November 6 by ... global recognition and funding program that honors individuals serving ... as the “Nobel Prize for Child Advocates,” this year’s ... that benefit children in countries around the world dealing ...
(Date:9/16/2014)... Tara Haelle HealthDay ... A new blood test is the first objective scientific way ... The test measures the levels of nine genetic indicators ... could also determine who will respond to cognitive behavioral therapy, ... and could show whether the therapy worked, Northwestern University researchers ...
(Date:9/16/2014)... Oncology (ASTRO) has selected C.M. Charlie Ma, PhD, Professor, ... Director of Medical Physics at Fox Chase Cancer ... members selected to receive the Fellow of ASTRO designation ... September 16, at the ASTRO,s 56th Annual Meeting in ... is a great honor and we are thrilled that ...
Breaking Medicine News(10 mins):Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3
... Cancer Center, New York, and colleagues conducted a systematic ... harms of low-dose computerized tomography (LDCT) screening for lung ... "Most patients are diagnosed with advanced disease, resulting in ... "Renewed enthusiasm for lung screening arose with the advent ...
... - Treatment of obstructive sleep apnea (OSA) in children ... and executive function, according to a new study. ... in attention, cognition, and executive function," said lead author ... Sleep Center and University of Colorado Denver. "Our study ...
... More than 4.7 million Americans are bitten by dogs each ... than age 14, experts say. During National Dog Bite ... Pediatrics is joining with the American Veterinary Medical Association and ... They offer many tips to help parents protect their ...
... FRIDAY, May 18 (HealthDay News) -- One-third of homeless people in ... general population, a new study finds. It might seem that ... for weighing too little, according to the researchers at Harvard Medical ... Kingdom. But, the high rate of obesity among homeless people ...
... Since Sept. 11, it has become increasingly common ... or "infidels" to hell, but this has never ... State University professor who recently published a first-of-its-kind book ... Western writers believe condemnation and dehumanization of non-Muslims make ...
... May 18 (HealthDay News) -- Young people can easily buy ... wide range of advertising and marketing efforts from the alcohol ... the Center on Alcohol Marketing and Youth at the Johns ... alcohol messages, which may contribute to the 4,700 alcohol-related deaths ...
Cached Medicine News:Health News:Low-dose CT screening may benefit individuals at increased risk for lung cancer 2Health News:Treatment of childhood OSA reverses brain abnormalities 2Health News:Keeping Your Family Safe From Dog Bites 2Health News:One-Third of U.S. Homeless Population Is Obese: Study 2Health News:What does Islam say about the fate of others? 2Health News:Underage Drinkers Can Easily Order Alcohol From the Internet 2
Esophageal and Anorectal Solid State Catheter Adapter Cable for Polygraf ID...
... The ITREL 3 is a battery powered ... the U.S., ,Enterra™ Therapy is indicated ... vomiting associated with gastroparesis when conventional drug ... symptons for diabetic or idiopathic patients., ...
... diagnosis of influenza A and ... due to the availability of ... of influenza using Clearview Exact ... lead to reduced hospital stays, ...
... OMT test is a single use, qualitative, ... of antibodies to Human Immunodeficiency Virus Type ... human oral,mucosal transudate specimens. It is intended ... the clinical diagnosis of HIV,infection. This test ...
Medicine Products: